TABLE 4.
NNRTI nonpolymorphic treatment-selected mutations
| Position | Consa | TSM(s)b | No. of individuals |
|
|---|---|---|---|---|
| RTI treated | RTI naive | |||
| 94 | I | L0.6 | 28,810 | 52,041 |
| 98 | A | G5.7 | 28,802 | 52,042 |
| 100 | L | I3.6 | 28,796 | 51,999 |
| 101 | K | E6.6 P1.3 H1.1 N0.4 T0.3 A0.2 D0.1 | 28,794 | 52,039 |
| 102 | K | N0.4 G0.1 | 28,804 | 52,028 |
| 103 | K | N30.7 S1.6 T0.2 H0.1 | 28,805 | 52,032 |
| 105 | S | T0.2 | 28,808 | 52,045 |
| 106 | V | M4.0 A1.4 | 28,805 | 52,045 |
| 108 | V | I7.4 | 28,808 | 52,043 |
| 132 | I | L0.7 | 28,800 | 52,037 |
| 138 | E | Q1.0 K0.5 T0.1 | 28,798 | 52,024 |
| 139 | T | R0.8 | 28,798 | 52,037 |
| 178 | I | F0.2 | 28,781 | 52,001 |
| 179 | V | F0.2 L0.1 M0.1 | 28,774 | 52,010 |
| 181 | Y | C16.6 I0.7 V0.5 F0.2 G0.1 N0.1 | 28,780 | 52,016 |
| 188 | Y | L3.7 C0.8 H0.7 F0.4 | 28,758 | 52,014 |
| 190 | G | A12.7 S2.3 E0.4 Q0.3 C0.1 | 28,771 | 52,015 |
| 221 | H | Y6.1 C0.1 | 28,565 | 50,963 |
| 225 | P | H3.7 | 28,386 | 50,583 |
| 227 | F | L2.3 Y0.2 | 28,165 | 50,128 |
| 230 | M | L1.4 | 28,081 | 49,720 |
| 232 | Y | H0.3 | 27,827 | 49,437 |
| 234 | L | I0.2 | 27,760 | 49,216 |
| 238 | K | T1.9 N0.4 | 27,404 | 47,232 |
| 240 | T | K0.1 | 23,831 | 46,204 |
| 241 | V | M0.2 | 23,586 | 44,549 |
| 242 | Q | H0.9 L0.2 K0.1 | 23,529 | 43,984 |
| 318 | Y | F1.3 | 10,809 | 15,668 |
| 348 | N | I13.0 T0.8 | 6,367 | 5,528 |
| 404 | E | N1.3 | 1,207 | 3,663 |
a
Cons, consensus.
b
Nonpolymorphic treatment-selected mutations (TSMs) in boldface were previously reported as being associated with drug resistance (18).